Tgfbrap1-KO Mouse

Tgfbrap1, also known as TGF-β receptor-associated binding protein 1, plays important roles in multiple biological processes. It is involved in the TGF-β signaling pathway, which is crucial for cell growth, differentiation, and tissue homeostasis [1,2,3,4,6,7,8]. Genetic studies on Tgfbrap1 can provide insights into its function and its implications in various diseases.

In pulmonary fibrosis, Chitinase 1 (CHIT1) regulates the TGF-β/SMAD7 pathway via interaction with Tgfbrap1 and FOXO3, highlighting its role in the pathogenesis of the disease [1,5,8]. In goose follicular granulosa cells, knockdown of Tgfbrap1 reduces apoptosis and enhances the secretion of E2 and P4, suggesting its role in regulating follicular development [2]. A variant at Tgfbrap1 is significantly associated with type 2 diabetes mellitus and affects diabetes-related miRNA expression, indicating its contribution to the genetic susceptibility of T2DM [3]. Also, the A variant of rs17687727 in Tgfbrap1 influences the susceptibility to antituberculosis drug-induced liver injury in the Han Chinese population [4]. In liver cancer, Tgfbrap1 stabilizes TGF-β receptor type 1, dictating feedback activation of the TGF-β signaling pathway to maintain liver cancer stemness and drug resistance [6]. Piperine, in protecting against acetaminophen-induced hepatotoxicity, may act through regulation of Tgfbrap1 [7]. Overexpression of Tgfbrap1, a CORVET-specific subunit, decreases the amount of assembled HOPS complex, affecting autophagosome-lysosome fusion and lysosomal hydrolase delivery [9].

In conclusion, Tgfbrap1 is a key player in the TGF-β signaling pathway and is involved in multiple biological processes such as tissue fibrosis, follicular development, and disease-related miRNA regulation. Its variants are associated with type 2 diabetes and antituberculosis drug-induced liver injury. The study of Tgfbrap1 in various in vivo models has provided valuable insights into its functions in these disease areas, contributing to our understanding of disease mechanisms and potential therapeutic targets.